Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Kristian Reich, Kim A. Papp, Andrew Blauvelt, Richard G. Langley, April Armstrong, Richard B. Warren, Kenneth B. Gordon, Joseph F. Merola, Yukari Okubo, Cynthia Madden, Maggie Wang, Christopher Cioffi, Veerle Vanvoorden, Mark Lebwohl
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial'. Together they form a unique fingerprint.